Lipid profile changes associated with changing available formulary statins: Removing higher potency agents

American Journal of Managed Care

Volumn 15, Issue 7, 2009, Pages 409-414

  Longyhore, Daniel S ^a   Stockton, Casey McNulty ^a   Thomas, Marie Roke ^a  

^a WILKES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG FORMULARY; DRUG POTENCY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FASTING; FORMULARIES, HOSPITAL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; PYRROLES; RETROSPECTIVE STUDIES; TRIGLYCERIDES; UNITED STATES;

EID: 67650822428     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Henry J. Kaiser Family Foundation. Prescription DrugTrends. September 2008. http://www.kff.org/rxdrugs/upload/3057-07.pdf. Accessed October 20, 2008.
2. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs. Food Drug Law J. 1998;53(1):25-34.
3. Sipkoff M. Getting serious about generics. Manag Care. 2003;12(1):36-39.
4. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8):1182-1186.
5. Top 200 drugs for 2007 by sales, http://www.drugs.com/top200. html. Accessed August 12, 2008.
6. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24(suppl 3):65-78.
7. Patel RJ, Gray DR, Pierce R, Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care. 1999;5(4):465-474. (Pubitemid 29202926)
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5);487-497.
9. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698. (Pubitemid 37466137)
10. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction apears in N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004;350(15):1495-1504.
11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82(1):128]. Am J Cardiol. 1998;81(5):582-587.
12. Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008;9(5):669-676. (Pubitemid 351566187)
13. Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006;12(15 suppl):S412-S423.
14. Bullano MF, Kamat S. Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low- densitylipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007;64(3):276-284. (Pubitemid 46193258)
15. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther. 2007;29(11):2385-2394.
16. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006;26(4):469-478.
17. Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008;28(5):553-561.
18. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. Highdensity lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary PreventionTrial. Circulation. 1986;74(6):1217-1225. (Pubitemid 17189240)
19. Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3).720-732.
20. Lipitor [package insert]. NewYork: Parke-Davis & Pfizer Inc; 2009.
21. Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
22. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co; 2008.
23. van der Harst P, Asselbergs FW, Hillege HL, et al; PREVEND-IT Investigators. Effect of withdrawal of pravastatin therapy on C- reactive protein and low-density lipoprotein cholesterol. Am J Cardiol. 2007;100(10):1548-1551. (Pubitemid 350050860)
24. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avom J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. (Pubitemid 34787476)
25. Mohler P, Nolan S. What every physician should know about generic drugs. Fam Pract Manag. 2002;9(3):45-46.